GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (TSXV:APC.H) » Definitions » Shares Outstanding (EOP)

Advanced Proteome Therapeutics (TSXV:APC.H) Shares Outstanding (EOP) : 41.13 Mil (As of Apr. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Advanced Proteome Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Advanced Proteome Therapeutics's shares outstanding for the quarter that ended in Apr. 2023 was 41.13 Mil.

Advanced Proteome Therapeutics's quarterly shares outstanding stayed the same from Jan. 2023 (41.13 Mil) to Apr. 2023 (41.13 Mil).

Advanced Proteome Therapeutics's annual shares outstanding increased from Jul. 2021 (37.75 Mil) to Jul. 2022 (39.68 Mil). It means Advanced Proteome Therapeutics issued new shares from Jul. 2021 to Jul. 2022 .


Advanced Proteome Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Advanced Proteome Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Shares Outstanding (EOP) Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.05 21.00 27.09 37.75 39.68

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.68 39.68 39.68 41.13 41.13

Competitive Comparison of Advanced Proteome Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Shares Outstanding (EOP) falls into.



Advanced Proteome Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Advanced Proteome Therapeutics  (TSXV:APC.H) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Advanced Proteome Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (TSXV:APC.H) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (TSXV:APC.H) Headlines

No Headlines